menu
    • menu
    [{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"SMITH & NEPHEW INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SMITH & NEPHEW INC \/ Undisclosed"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"SMITH & NEPHEW INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SMITH & NEPHEW INC \/ Undisclosed"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"SMITH & NEPHEW INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SMITH & NEPHEW INC \/ Undisclosed"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Healthpoint","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"HP802-247","moa":"Keratinocyte\/Fibroblast","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"SMITH & NEPHEW INC \/ SMITH & NEPHEW INC","highestDevelopmentStatusID":"10","companyTruncated":"SMITH & NEPHEW INC \/ SMITH & NEPHEW INC"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Peptide, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Becaplermin","moa":"Platelet-derived growth factor receptor","graph1":"Podiatry","graph2":"Approved FDF","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Healiva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocyte","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SMITH & NEPHEW INC \/ Healiva","highestDevelopmentStatusID":"8","companyTruncated":"SMITH & NEPHEW INC \/ Healiva"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"SMITH & NEPHEW INC","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"SMITH & NEPHEW INC \/ SMITH & NEPHEW INC","highestDevelopmentStatusID":"11","companyTruncated":"SMITH & NEPHEW INC \/ SMITH & NEPHEW INC"}]

    Find Clinical Drug Pipeline Developments & Deals by SMITH & NEPHEW INC

    Menu

    SMITH & NEPHEW INC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Becaplermin

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Lynch Regenerative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lynch Regenerative Acquires REGRANEX® Gel for Soft Tissue Regeneration

                            Details : Under the acquisition, Lynch holds the exclusive rights to Regranex (becaplermin) gel and recombinant purified platelet-derived growth factor (PDGF). It is being indicated for diabetic foot ulcer.

                            Product Name : Regranex

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            March 31, 2025

                            Lead Product(s) : Becaplermin

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Lynch Regenerative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Healiva

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

                            Details : The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy.

                            Product Name : Epidex

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            June 01, 2022

                            Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Healiva

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase IV

                            Recipient : Henry Ford Health System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Bioinductive Implant for Tennis Elbow (Lateral Epicondylitis)

                            Details : This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Tennis Elbow.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 24, 2018

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase IV

                            Recipient : Henry Ford Health System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers

                            Details : Santyl is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pressure Ulcer.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 24, 2016

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of Santyl Within an Accountable Care Organization

                            Details : Santyl is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pressure Ulcer.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 23, 2016

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Podiatry

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of Santyl in Diabetic Foot Ulcers

                            Details : Santyl is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 21, 2015

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed

                            SMITH & NEPHEW INC

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Healthpoint

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

                            Details : HP802-247 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leg Ulcer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 03, 2012

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Healthpoint

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth